Market Cap 231.03M
Revenue (ttm) 0.00
Net Income (ttm) -51.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 909,600
Avg Vol 1,698,510
Day's Range N/A - N/A
Shares Out 32.59M
Stochastic %K 61%
Beta 3.60
Analysts Strong Sell
Price Target $26.50

Company Profile

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company's lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 561 8600
Address:
155 Bovet Road, Suite 303, San Mateo, United States
Whiskeyunderthebed
Whiskeyunderthebed May. 27 at 3:04 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 27 at 2:58 PM
$SGMT So it looks like they continue to explore the use of Resmetirom in NASH.
1 · Reply
DARKP00L
DARKP00L May. 27 at 11:42 AM
$SGMT 07:16 on May. 27 2026 Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased #tradeideas
0 · Reply
dick_dasterdly
dick_dasterdly May. 26 at 7:06 PM
0 · Reply
SYC80
SYC80 May. 21 at 5:29 PM
$SGMT Feels like one of those names people ignore… until they suddenly don’t.
1 · Reply
shibadad
shibadad May. 20 at 4:58 PM
$SGMT I shared this study a few months ago. This puts the Chinese acne market (prescription and OTC) at nearly $12B. If Ascletis can capture 5% of the market, that's nearly $50-60M in annual royalty revenue to SGMT. https://mobilityforesights.com/product/china-acne-treatment-market
1 · Reply
shibadad
shibadad May. 20 at 1:12 PM
$SGMT Ran across this study for those who aren't aware of the size of the global acne market. Antibiotics make up 21.5% of the $9B market. The threat of antibiotic resistance could make denifanstat the first in line treatment if approved. https://www.coherentmarketinsights.com/industry-reports/acne-medication-market#:~:text=Source%3A%20European%20Medicines%20Agency),adherence%20to%20dermatological%20treatment%20protocols.
1 · Reply
shibadad
shibadad May. 19 at 6:53 PM
$SGMT While there was little new from the firseide, I think the most important tidbit was Happel saying (19:00 mark) that the FDA encouraged them to look at the 12–17-year-old population because of the safety profile of denifanstat compared to Accutane. At its commercial peak in 2000, global sales of Accutane hit $759.4 million (equivalent to well over $1.3 billion today) before the side effects were discovered.
0 · Reply
shibadad
shibadad May. 19 at 6:44 PM
$SGMT Highlights from today's fireside: - awful sound quality full of background noise and distractions (someone actually sat in front of the camera initially). Poor job by HCW Happel and Grauer were presenting: - no advances in acne since Accutane (isotretinoin) in 1992. - isotretinoin requires strict monitoring and carries a REMS label because of the side effects. - younger demographic might be a challenge to maintain adherence to drug. Need to recruit both patient and parent. Will guarantee patients open label stage if they are on placebo for 12 weeks. - denifanstat is not a "cure" and acne will return if discontinued. - could see greater efficacy with TVB 3567 - FDA encouraged SGMT to look at the younger population (12-17 year olds) because of the safety profile of denifanstat and the problems with Accutane in that group. - looking at both deni and TVB 3567 as a topical. IND expected in 2028.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 19 at 6:25 PM
0 · Reply
Latest News on SGMT
Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)

2026-05-12T11:45:46.000Z - 15 days ago

Sagimet Biosciences reports Q1 EPS (33c), consensus (35c)


Sagimet Biosciences Quarterly report: Q1 2026

May 12, 2026, 7:00 AM EDT - 15 days ago

Sagimet Biosciences Quarterly report: Q1 2026


Sagimet Biosciences Earnings release: Q1 2026

May 12, 2026, 7:00 AM EDT - 15 days ago

Sagimet Biosciences Earnings release: Q1 2026


Sagimet Biosciences Transcript: Status update

Apr 30, 2026, 2:00 PM EDT - 26 days ago

Sagimet Biosciences Transcript: Status update


Sagimet Biosciences Slides: Status update

Apr 30, 2026, 2:00 PM EDT - 26 days ago

Sagimet Biosciences Slides: Status update


3 Penny Stocks to Watch Now, 4/28/26

2026-04-28T18:07:00.000Z - 4 weeks ago

3 Penny Stocks to Watch Now, 4/28/26

HTCO YAAS


Sagimet Biosciences holds a conference call

2026-04-28T17:15:16.000Z - 4 weeks ago

Sagimet Biosciences holds a conference call


TD Cowen establishes $21 price target for Sagamet Bioscinces

2026-04-28T12:19:03.000Z - 4 weeks ago

TD Cowen establishes $21 price target for Sagamet Bioscinces


Sagimet Biosciences Provides Strategic and Corporate Updates

Apr 27, 2026, 7:00 AM EDT - 4 weeks ago

Sagimet Biosciences Provides Strategic and Corporate Updates


Sagimet Biosciences Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

Sagimet Biosciences Proxy statement: Proxy filing


Sagimet Biosciences initiated with a Buy at Rodman & Renshaw

2026-03-26T11:46:26.000Z - 2 months ago

Sagimet Biosciences initiated with a Buy at Rodman & Renshaw


Sagimet Biosciences reports Q4 EPS (29c), consensus (43c)

2026-03-11T11:37:39.000Z - 2 months ago

Sagimet Biosciences reports Q4 EPS (29c), consensus (43c)


Sagimet Biosciences Earnings release: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 2 months ago

Sagimet Biosciences Earnings release: Q4 2025


Sagimet Biosciences Annual report: Q4 2025

Mar 11, 2026, 7:00 AM EDT - 2 months ago

Sagimet Biosciences Annual report: Q4 2025


Sagimet Biosciences initiated with a Buy at Guggenheim

2026-02-03T12:21:07.000Z - 4 months ago

Sagimet Biosciences initiated with a Buy at Guggenheim


Sagimet Biosciences initiated with an Equal Weight at Barclays

2026-01-27T21:30:19.000Z - 4 months ago

Sagimet Biosciences initiated with an Equal Weight at Barclays


Sagimet Biosciences Earnings release: Q3 2025

Nov 13, 2025, 7:00 AM EST - 6 months ago

Sagimet Biosciences Earnings release: Q3 2025


Sagimet Biosciences Quarterly report: Q3 2025

Nov 13, 2025, 7:00 AM EST - 6 months ago

Sagimet Biosciences Quarterly report: Q3 2025


Sagimet Biosciences Earnings release: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Sagimet Biosciences Earnings release: Q2 2025


Sagimet Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 7:00 AM EDT - 10 months ago

Sagimet Biosciences Quarterly report: Q2 2025


Sagimet Biosciences Slides: Investor Presentation

Aug 12, 2025, 7:00 AM EDT - 10 months ago

Sagimet Biosciences Slides: Investor Presentation


Sagimet Biosciences Transcript: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event


Sagimet Biosciences Press release: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Press release: KOL Event


Sagimet Biosciences Slides: KOL Event

Jun 16, 2025, 2:00 PM EDT - 1 year ago

Sagimet Biosciences Slides: KOL Event


Sagimet Biosciences Slides: Corporate Presentation

Jun 5, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Slides: Corporate Presentation


Sagimet Biosciences Transcript: KOL Event

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Transcript: KOL Event


Sagimet Biosciences Slides: KOL Event

May 29, 2025, 1:00 PM EDT - 1 year ago

Sagimet Biosciences Slides: KOL Event


Sagimet Biosciences Earnings release: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q1 2025


Sagimet Biosciences Quarterly report: Q1 2025

May 8, 2025, 7:00 AM EDT - 1 year ago

Sagimet Biosciences Quarterly report: Q1 2025


Sagimet Biosciences Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Proxy statement: Proxy Filing


Sagimet Biosciences Earnings release: Q4 2024

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q4 2024


Sagimet Biosciences Annual report: Q4 2024

Mar 12, 2025, 7:30 AM EDT - 1 year ago

Sagimet Biosciences Annual report: Q4 2024


Sagimet Biosciences Earnings release: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences Earnings release: Q3 2024


Sagimet Biosciences Quarterly report: Q3 2024

Nov 14, 2024, 8:00 AM EST - 1 year ago

Sagimet Biosciences Quarterly report: Q3 2024


Sagimet Biosciences Quarterly report: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Quarterly report: Q2 2024


Sagimet Biosciences Earnings release: Q2 2024

Aug 14, 2024, 8:00 AM EDT - 1 year ago

Sagimet Biosciences Earnings release: Q2 2024


Sagimet Biosciences Transcript: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Study Update


Sagimet Biosciences Press release: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Press release: Study Update


Sagimet Biosciences Slides: Study Update

Jun 13, 2024, 12:30 PM EDT - 2 years ago

Sagimet Biosciences Slides: Study Update


Sagimet Biosciences Transcript: Investor & Analyst Day 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Transcript: Investor & Analyst Day 2024


Sagimet Biosciences Slides: FY 2024

May 23, 2024, 1:00 PM EDT - 2 years ago

Sagimet Biosciences Slides: FY 2024


Sagimet Biosciences Quarterly report: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Sagimet Biosciences Quarterly report: Q1 2024


Sagimet Biosciences Earnings release: Q1 2024

May 13, 2024, 7:00 AM EDT - 2 years ago

Sagimet Biosciences Earnings release: Q1 2024


Sagimet Biosciences Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Proxy statement: Proxy Filing


Sagimet Biosciences Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Proxy statement: Proxy Filing


Sagimet Biosciences Earnings release: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Earnings release: Q4 2023


Sagimet Biosciences Annual report: Q4 2023

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Annual report: Q4 2023


Sagimet Biosciences Slides: Corporate Presentation

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Sagimet Biosciences Slides: Corporate Presentation


Whiskeyunderthebed
Whiskeyunderthebed May. 27 at 3:04 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 27 at 2:58 PM
$SGMT So it looks like they continue to explore the use of Resmetirom in NASH.
1 · Reply
DARKP00L
DARKP00L May. 27 at 11:42 AM
$SGMT 07:16 on May. 27 2026 Sagimet Biosciences Presents Two Posters At EASL 2026; Denifanstat/Resmetirom Phase 1 Data Selected As Best Of EASL, With Additional Preclinical Mechanism Findings Showcased #tradeideas
0 · Reply
dick_dasterdly
dick_dasterdly May. 26 at 7:06 PM
0 · Reply
SYC80
SYC80 May. 21 at 5:29 PM
$SGMT Feels like one of those names people ignore… until they suddenly don’t.
1 · Reply
shibadad
shibadad May. 20 at 4:58 PM
$SGMT I shared this study a few months ago. This puts the Chinese acne market (prescription and OTC) at nearly $12B. If Ascletis can capture 5% of the market, that's nearly $50-60M in annual royalty revenue to SGMT. https://mobilityforesights.com/product/china-acne-treatment-market
1 · Reply
shibadad
shibadad May. 20 at 1:12 PM
$SGMT Ran across this study for those who aren't aware of the size of the global acne market. Antibiotics make up 21.5% of the $9B market. The threat of antibiotic resistance could make denifanstat the first in line treatment if approved. https://www.coherentmarketinsights.com/industry-reports/acne-medication-market#:~:text=Source%3A%20European%20Medicines%20Agency),adherence%20to%20dermatological%20treatment%20protocols.
1 · Reply
shibadad
shibadad May. 19 at 6:53 PM
$SGMT While there was little new from the firseide, I think the most important tidbit was Happel saying (19:00 mark) that the FDA encouraged them to look at the 12–17-year-old population because of the safety profile of denifanstat compared to Accutane. At its commercial peak in 2000, global sales of Accutane hit $759.4 million (equivalent to well over $1.3 billion today) before the side effects were discovered.
0 · Reply
shibadad
shibadad May. 19 at 6:44 PM
$SGMT Highlights from today's fireside: - awful sound quality full of background noise and distractions (someone actually sat in front of the camera initially). Poor job by HCW Happel and Grauer were presenting: - no advances in acne since Accutane (isotretinoin) in 1992. - isotretinoin requires strict monitoring and carries a REMS label because of the side effects. - younger demographic might be a challenge to maintain adherence to drug. Need to recruit both patient and parent. Will guarantee patients open label stage if they are on placebo for 12 weeks. - denifanstat is not a "cure" and acne will return if discontinued. - could see greater efficacy with TVB 3567 - FDA encouraged SGMT to look at the younger population (12-17 year olds) because of the safety profile of denifanstat and the problems with Accutane in that group. - looking at both deni and TVB 3567 as a topical. IND expected in 2028.
1 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 19 at 6:25 PM
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed May. 19 at 4:44 PM
1 · Reply
shibadad
shibadad May. 19 at 1:03 PM
$SGMT The company is doing a fireside chat at HCW at 2pm. It's unlikely there will be any new information but you never know. HCW was one of the co-leads in the latest secondary and has a PT of $29.
1 · Reply
DARKP00L
DARKP00L May. 19 at 12:55 PM
$SGMT 08:50 on May. 19 2026 Citizens Maintains Market Outperform on Sagimet Biosciences, Lowers Price Target to $12 #tradeideas
1 · Reply
shibadad
shibadad May. 18 at 2:05 PM
$SGMT Two large holders (Woodline and Baker) held steady in Q1 with Affinity selling in Q1. We know Woodline bought shares in the secondary offering along with Blue Owl. Not a fan of Woodline being such a large shareholder. They seem to be a little flighty and more than happy to sell any rip.
0 · Reply
nastento
nastento May. 15 at 4:15 PM
$SGMT close the gap and let me grab some cheap shares
1 · Reply
marquesr1
marquesr1 May. 15 at 4:13 PM
$SGMT Sgmt is now about to fill the gap below once it fills i will close my short position out, thanks. Bearish short term.
2 · Reply
wdfrsd
wdfrsd May. 15 at 10:12 AM
0 · Reply
shibadad
shibadad May. 15 at 2:21 AM
$SGMT Blue Owl sold 900k shares in Q1, only to participate in the secondary offering in April? Seems a little fishy. Feels like they pushed it lower to get more shares in the secondary offering. If Q2 shows they bought like 2M shares in the secondary, you know they manipulated the secondary to their benefit.
2 · Reply
rational1
rational1 May. 13 at 5:25 PM
$SGMT In case you were wondering why it's down today.
1 · Reply
DarkH0rse91
DarkH0rse91 May. 13 at 3:45 PM
$ALT $GUTS $HUMA $SGMT $SLS agreed. Was up 9k will rebuy then sell again
1 · Reply
BioRich
BioRich May. 13 at 3:22 PM
$SLS Again, the $SLS and $ALT Nations can hate their Mayor, but he's really good at what he does. Took 40% gain in $SGMT (which I was very strong in and still dig) and rolled it into $HUMA (+33.75%) $GUTS (+32.66%), LGND (-8.66%) and VVOS (-13.22%), while SGMT went down ~3%. This is how it's done folks. For those that didn't sell at $6.60 last evening, you're already down 12.3% because you got greedy instead. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! (Can only tag 5 tickers so will add cash tags to LGND and VVOS in comments, not omitting).
4 · Reply
dick_dasterdly
dick_dasterdly May. 13 at 3:57 AM
$SGMT Fortifying the position here and now it sits in Mr. Roth. No need to monitor here anymore. Quarterly check ins. That's it. I know where this is headed.
0 · Reply